ArticleBiomedical journal2021
Increased macrophage activation marker soluble CD163 is associated with graft dysfunction and metabolic derangements in renal transplant recipients.
Article in Biomedical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Novel insights and an updated review of metabolic syndrome in immune-mediated organ transplant rejection.Frontiers in immunology · 2025Review
- The best protection is early detection: Fostering timely and accurate screening.Biomedical journal · 2021Article
- Dyslipidemia is associated with monocyte lipid metabolic reprogramming in Guillain-Barré syndrome.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal allograft is vulnerable to numerous insults and is associated with metabolic derangements. Macrophages are regulators of inflammation and play a role in obesity, lipid metabolism and insulin resistance (IR). The present study was designed to assess macrophage activation, reflected by serum soluble CD163 (sCD163), in renal transplant recipients (RTR) and its relation to chronic allograft dysfunction (CAD) and metabolic derangements.
methodsFifty recipients of renal transplantation (RT) [22 with stable renal function and 28 with CAD] and 20 age- and sex-matched healthy controls were enrolled in the study. Serum sCD163 and high sensitivity C-reactive protein (hsCRP) were measured using enzyme-linked immunosorbent assay. Anthropometric measurements, renal function, lipid profile and homeostatic model assessment of IR (HOMA-IR) were estimated. Renal interstitial fibrosis (IF) was graded in renal biopsies of CAD.
resultsRTR mean age was 38.84 ± 9.28 years and 83% of them were males. Post-transplant dyslipidemia, diabetes and IR (HOMA-IR >2) were present in 42%, 24% and 86% of RTR respectively. Serum sCD163 levels were significantly higher in RTR with stable renal function and CAD than in healthy controls (814.41 ± 59.62 ng/ml and 1021.21 ± 120.82 ng/ml vs. 602.90 ± 114.98 ng/ml respectively) and in RTR with CAD than in patients with stable renal function (p < 0.001). Serum sCD163 levels were positively correlated with body mass index, waist-to-hip ratio, worsening renal function, dyslipidemia, HOMA-IR and serum hsCRP in RTR and with the degree of renal IF in RTR with CAD (p < 0.05). ROC curve showed that serum sCD163 was superior to serum hsCRP in detecting CAD after RT (AUC = 0.972 vs. 0.753 respectively, p = 0.001).
conclusionMacrophage activation, reflected by increased circulating sCD163, may play a role in the development of CAD and metabolic derangements after RT. Serum sCD163 could be a potential biomarker for renal allograft dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.